Cancer Therapeutics CRC chair male

Dr Tony Evans


  • Core Skills:
    Managing collaborative research and industry drug development
Cancer Therapeutics CRC chair male

Dr Tony Evans was appointed to the Board in 2007 and to the role of Chair in 2011. Prior to his appointment as Chair, Dr Evans served as CEO of Cancer Therapeutics CRC from 2008 to 2011.

Dr Evans has also been a director of Biolayer Corporation, Neurodiscovery, Coridon, Dendright, Promics, Q-Pharm and Spinifex. From 1988 to 1997 he worked in California, USA at Genentech then Onyx Pharmaceuticals.  On returning to Australia, he was appointed CEO and director of the CRC for Diagnostic Technologies and later, CEO and director of Xenome.

Dr Evans holds a BSc from the University of Sheffield, UK and a PhD from the Australian National University.  He has held postdoctoral fellowships in the Heidelberg Department of Medicine,Victoria, the University of Calgary and the University of North Carolina.